Alamar Biosciences, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Arrangements
During the three months ended September 30, 2026, the following directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted a “Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K, that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act:
| Type of Trading Arrangement | ||||||
| Name and Title | Action | Date | Rule 10b5-1* | Non-Rule 10b5-1** | Aggregate Number of Shares to Be Sold | Expiration Date |
|---|---|---|---|---|---|---|
| Yuling Luo, Ph.D., Co-Founder, Chief Executive Officer and Chair of the Board | Adoption | September 16, 2026 | X | Up to 150,000 (1) | October 29, 2027 | |
| Shiping Chen, Ph.D., Co-Founder, Chief Operating Officer and Director | Adoption | September 16, 2026 | X | Up to 73,200 | July 1, 2027 | |
| Timothy White, President | Adoption | September 16, 2026 | X | Up to 149,360 (2) | September 30, 2027 | |
- A contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
** A “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(c) of Regulation S-K.
(1) Consists of up to 90,000 shares held by Dr. Luo and up to 60,000 shares held by Dr. Luo's spouse, Limin Chen, each to be sold under a single trading arrangement.
(2) Includes up to 79,360 shares issuable upon the exercise of stock options.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.